The FLT3 gene in humans encodes the protein FLT3, also known as Fms-like tyrosine kinase 3 (CD135). The class III receptor tyrosine kinase family includes FLT3, a cytokine receptor.FLT3 is the cytokine Flt3 ligand (FLT3L)'sreceptor. On the surface of many hematopoietic progenitor cells, FLT-3 is expressed. The normal development of hemopoietic stem cells and progenitor cells depends on FLT3 signaling. One of the genes with the highest frequency of mutations in acute myeloid leukemia (AML) is FLT3. Furthermore, high FLT3 levels in blast cells from some AML patients without FLT3 mutations have been observed. The prognosis may be worse when these levels are high. Cell proliferation, differentiation, and survival are influenced by FLT3 signaling. FLT3 is crucial for the growth of lymphocytes (B and T cells), but not for the growth of other blood cells. The cytokines TNF-Alpha and TGF-Beta both inhibit FLT3 activity.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69488 | BPR1K871 (DBPR114) | 2443767-35-7 | BPR1K871 (DBPR114) is a potent and specific FLT3/AURKA dual (bifunctional) inhibitor (antagonist) with IC50s of 19 nM and 22 nM for FLT3 and AURKA respectively. |
|
V69292 | Dovitinib lactate (CHIR-258 lactate; TKI-258 lactate) | 692737-80-7 | Dovitinib lactate (TKI258 lactate) is a multi-target tyrosine kinase inhibitor, inhibiting FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β with IC50s of 1, 2, 8/9 respectively. |
|
V69283 | Dovitinib-d8 (Dovitinib d8) | 1246819-84-0 | Dovitinib-d8 is the deuterated form of Dovitinib. |
|
V69489 | FLT3-IN-10 | 2088735-51-5 | FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). |
|
V69500 | FLT3-IN-18 | 752191-77-8 | FLT3-IN-18 is a potent and specific FLT3 inhibitor (antagonist) with IC50 of 0.003 μM. |
|
V69492 | FLT3-IN-19 | 2237234-48-7 | FLT3-IN-19 (Comp 50) is a potent and specific FLT3 inhibitor (antagonist) with IC50 of 0.213 nM. |
|
V69490 | FLT3-IN-6 | 2377141-31-4 | FLT3-IN-6 is a potent and specific inhibitor of FLT3-ITD (FLT3 mutant) with IC50 of 1.336 nM. |
|
V2516 | HM43239 | 2569527-64-4 | HM-43239 is a novel,selectively and orally active small molecule inhibitor of FLT3. |
|
V69496 | HP1142 | 381173-58-6 | HP1142 is a potent and specific inhibitor of the FLT3 receptor tyrosine kinase (FLT3/ITD mutation). |
|
V69493 | HP1328 | 2245074-20-6 | HP1328 is a potent inhibitor of FLT3 receptor tyrosine kinase (FLT3/ITD mutated). |
|
V69495 | LT-540-717 | 2143089-35-2 | LT-540-717 (compound 32) is a potent FLT3 inhibitor (IC50=0.62 nM) with antiproliferation activity. |
|
V69451 | MAX-40279 | 2070931-57-4 | MAX-40279 is a dual potent inhibitor of FLT3 kinase and FGFR kinase. |
|
V69452 | MAX-40279 hemiadipate | 2388506-44-1 | MAX-40279 hemiadipate is a dual potent inhibitor of FLT3 kinase and FGFR kinase. |
|
V69454 | MAX-40279 hemifumarate | 2388506-43-0 | MAX-40279 hemifumarate is a dual potent inhibitor of FLT3 kinase and FGFR kinase. |
|
V69453 | MAX-40279 hydrochloride | 2388506-51-0 | MAX-40279 HCl is a dual potent inhibitor of FLT3 kinase and FGFR kinase. |
|
V69491 | PHI-101 | 2127107-15-5 | PHI-101 is an orally bioactive FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. |
|
V5145 | Quizartinib HCl (AC-220; AC-010220) | 1132827-21-4 | Quizartinib HCl (formerly AC220 and AC010220) is a novel, second-generation, and orally bioavailable FLT3 tyrosine kinase inhibitor for Flt3 (ITD/WT) with IC50 of 1.1 nM/4.2 nM in MV4-11 and RS4;11 cells, respectively, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. |
|
V51528 | Tuspetinib (HM-43239) | 2294874-49-8 | Tuspetinib (HM43239) has activity against the sidewall FLT3 form with IC50s of 1.1 nM (FLT3 wild type), 1.8 nM (FLT3 ITD mutant) and 1.0 nM (FLT3 D835Y mutant). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
